A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels

Details for Australian Patent Application No. 2002239329 (hide)

Owner Allergan, Inc.

Inventors Ehring, George R.; Adorante, Joseph S; Donello, John E.

Agent Davies Collison Cave

Pub. Number AU-B-2002239329

PCT Pub. Number WO02/42842

Priority 60/252,771 22.11.00 US

Filing date 16 November 2001

Wipo publication date 3 June 2002

Acceptance publication date 10 August 2006

International Classifications

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

10 August 2006 Application Accepted

  Published as AU-B-2002239329

7 December 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002239330

2002239328